Welcome to our dedicated page for Lilly Eli & Co SEC filings (Ticker: LLY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Patent expiration dates for Trulicity, Mounjaro, and other blockbuster medicines mean every Eli Lilly disclosure can shift expectations for future cash flow. If you have ever searched for Eli Lilly SEC filings explained simply, you know how dense a pharmaceutical 10-K can be. Stock Titan’s AI reads each document the instant it posts to EDGAR and serves a concise summary that highlights clinical-trial outcomes, FDA correspondence, and global pricing risks—turning hundreds of pages into a five-minute briefing.
Need details from the latest Eli Lilly quarterly earnings report 10-Q filing or a quick take on cash used for R&D? Our platform flags segment revenue, pipeline spend, and patent-life tables while linking directly to the full text. The annual report is here as the Eli Lilly annual report 10-K simplified; Form 8-K alerts keep you current with trial readouts and collaborations—see Eli Lilly 8-K material events explained. When proxy season arrives, the Eli Lilly proxy statement executive compensation section breaks down option awards, pay-for-performance metrics, and governance votes, all with clear AI commentary.
Monitoring insider sentiment? Track Eli Lilly insider trading Form 4 transactions and receive Eli Lilly Form 4 insider transactions real-time notifications. Our dashboards group every Eli Lilly executive stock transactions Form 4 with trend charts so you can spot buying or selling patterns before the market reacts. Use the built-in tools for Eli Lilly earnings report filing analysis or simply browse by form if you prefer traditional reading. Whether you’re comparing quarter-over-quarter margins or understanding Eli Lilly SEC documents with AI, this page delivers every filing, every update, in a workflow that saves hours and sharpens your investment decisions.
Lemonade, Inc. (LMND) – Form 4 insider filing
CFO Timothy E. Bixby exercised 7,000 fully-vested employee stock options at an exercise price of $23.69, then sold the same 7,000 shares under a Rule 10b5-1 plan. The sales occurred on 18 Jul 2025 (6,000 sh. at $42.50) and 21 Jul 2025 (1,000 sh. at $42.70), generating gross proceeds of roughly $0.30 million versus an aggregate exercise cost of about $0.17 million.
After the transactions Mr. Bixby’s direct holding remains 263,393 common shares, unchanged from the level prior to the option exercises. He also retains 30,000 shares held indirectly through the Timothy E. Bixby Family Trust and 277,300 unexercised options expiring 25 Sep 2029.
The activity represents <0.02 % of LMND’s 67 million outstanding shares and appears routine portfolio diversification rather than a signal about business fundamentals. No other insiders transacted and no company cash was involved.
Ikena Oncology (IKNA) filed an 8-K announcing its board has declared a one-time special dividend of one contingent value right (CVR) for every outstanding share held as of the close of business on 24 Jul 2025. The CVRs are being issued in connection with the previously disclosed two-step merger with Inmagene Biopharmaceuticals.
Under the contemplated CVR Agreement, holders will receive (i) 100% of net proceeds, if any, from milestone, royalty or earn-out payments tied to dispositions of IKNA’s pre-merger assets and (ii) 90% of net proceeds from dispositions executed within one year after closing, both after permitted deductions (taxes, expenses, litigation and wind-down costs). If no such proceeds arise during the CVR term, the CVRs will expire worthless.
The merger structure remains unchanged: Merger Sub I merges into Inmagene, followed immediately by Inmagene into Merger Sub II, creating a wholly-owned subsidiary of IKNA. Forward-looking statements caution that closing conditions, expense control, legal proceedings and asset-sale milestones may affect both the merger and any CVR payout.
FAQ
What is the current stock price of Lilly Eli & Co (LLY)?
What is the market cap of Lilly Eli & Co (LLY)?
What is the primary focus of Lilly Eli & Co?
How does the company generate its revenue?
What sets Lilly Eli & Co apart in the pharmaceutical industry?
How does Lilly Eli & Co ensure the quality and safety of its products?
Where is Lilly Eli & Co headquartered?
What role does research and development play at Lilly Eli & Co?
How does Lilly Eli & Co contribute to global healthcare?
What are some key industry keywords associated with the company?
